News / Taiwan / economic_daily
Pegavision Q3 Growth Strong; Analysts Forecast 2024 EPS at NT$27.1
Health Technology · Medical Specialties · economic_daily · 2026-11-03
6491
Pegavision's Q3 revenue grew 19% YoY, driven by strong demand in Japan and Europe, with analysts projecting a full-year EPS of NT$27.1.
What Happened
Operational Performance: Pegavision reported robust third-quarter results, with revenue increasing 19% year-over-year and 6.3% quarter-over-quarter, driven by strong sales in Japan and Europe. Analysts expect the company to maintain double-digit year-over-year revenue growth in the fourth quarter as new capacity from the Daxi plant comes online.
Margin Analysis: While summer electricity costs and equipment expansion impacted margins, the easing of raw material costs and an increase in high-margin product shipments are expected to keep gross margins above 53% for the second half of the year. Analysts forecast a full-year EPS of NT$27.1, representing a 30.2% increase over the previous year.
Long-term Outlook: Looking toward 2027, analysts are optimistic about the contribution from the new Vietnam plant. The increasing penetration of silicone hydrogel and high-end optical products is expected to further optimize the product mix, driving continued growth in both revenue and profitability.
Investment Outlook: Given the company's overseas expansion and demand for high-end products, analysts maintain a positive outlook on Pegavision's mid-to-long-term performance. While the progress of capacity utilization and certification for new facilities remains a key factor to monitor, strong market demand provides a solid foundation for future growth.